Anti-Obesity Drugs: are They Worth It?

Abstract

Future Medicinal ChemistryVol. 3, No. 3 OpinionAnti-obesity drugs: are they worth it?Mark K Huntington & Roger A ShewmakeMark K Huntington† Author for correspondenceSioux Falls Family Medicine Residency Program, Center for Family Medicine, 1115 East Twentieth Street, Sioux Falls, SD 57110, USA; Department of Family Medicine, Sanford School of Medicine at The University of South Dakota, SD, USA. Search for more papers by this authorEmail the corresponding author at mark.huntington@usd.edu & Roger A ShewmakeSioux Falls Family Medicine Residency Program, Center for Family Medicine, 1115 East Twentieth Street, Sioux Falls, SD 57110, USA; Department of Family Medicine, Sanford School of Medicine at The University of South Dakota, SD, USASearch for more papers by this authorPublished Online:29 Mar 2011https://doi.org/10.4155/fmc.11.5AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: adverse effectscost–effectivenessefficacyobesityweight lossBibliography1 Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta- analysis. BMJ335(7631),1194–1199 (2007).Crossref, Medline, CAS, Google Scholar2 O’Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technology Assessment5(18),1–81 (2001).Crossref, Google Scholar3 Escott-Stump S. Nutrition and Diagnosis-Related Care. Lippincott Williams & Wilkins, PA, USA (2002).Google Scholar4 Hill JO, Hauptman J, Anderson JW et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am. J. Clin. Nutr.69(6),1108–1116 (1999).Crossref, Medline, CAS, Google Scholar5 Mechcatie E. FDA panel gives thumbs down to lorcaserin. Family Practice News40(17),9 (2010).Crossref, Google Scholar6 Turley A. Obesity drugs strive for US approval. Chemistry World7(9),2 (2010).Google Scholar7 Bray GA. Medications for obesity: mechanisms and applications. Clin. Chest Med.30(3),525–538 (2009).Crossref, Medline, Google Scholar8 Huntington MK, Shewmake RA. Weight-loss supplements: what is the evidence? S. D. Med.63(6),205–207 (2010).Medline, Google Scholar9 DeLaet D, Schauer D. Obesity in adults. Am. Fam. Physician.82(8),974–975 (2010).Google Scholar10 Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of dietary supplements for weight loss in the United States: results of a national survey. Obesity (Silver Spring)16(4),790–796 (2008).Crossref, Medline, CAS, Google Scholar11 Blanck HM, Serdula MK, Gillespie C et al. Use of nonprescription dietary supplements for weight loss is common among Americans. J. Am. Diet. Assoc.107(3),441–447 (2007).Crossref, Medline, Google Scholar12 Pi-Sunyer X, Kris-Etherton P. Improving health outcomes: future directions in the field. J. Am. Diet. Assoc.105(5 Suppl. 1),S14–S16 (2005).Crossref, Medline, Google Scholar13 Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes. Res.7(6),523–531 (1999).Crossref, Medline, CAS, Google Scholar14 Avenell A, Broom J, Brown TJ et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technology Assessment8(21),1–182 (2004).Crossref, Google Scholar15 Welbourn R, Pournaras D. Bariatric surgery: a cost-effective intervention for morbid obesity; functional and nutritional outcomes. Proc. Nutr. Soc.69(4),528–535 (2010).Crossref, Medline, Google Scholar16 Tsai AG, Asch DA, Wadden TA. Insurance coverage for obesity treatment. J. Am. Diet. Assoc.106(10),1651–1655 (2006).Crossref, Medline, Google Scholar101 Orexigen Therapeutics, Inc. CONTRAVE® Advisory Meeting Briefing Document (2010). Link.Google Scholar102 Tucker J. Arena pharma: understanding the market for anti-obesity drugs. 3rd September (2010). http://seekingalpha.com/article/223715-arena-pharma-understanding-the-market-for-anti-obesity-drugs (Accessed 3 December 2010).Google Scholar103 ScienceDaily. No evidence that popular slimming supplements facilitate weight loss, new research finds. 14th July (2010). www.sciencedaily.com/releases/2010/07/100712103445.htm (Accessed 3 December 2010).Google ScholarFiguresReferencesRelatedDetailsCited ByThe effects of medicinal herbs on gut microbiota and metabolic factors in obesity models: A systematic reviewDiabetes & Metabolic Syndrome: Clinical Research & Reviews, Vol. 16, No. 9Antiobesity Effects of Natural Products from an Epigenetic Perspective4-Aminophthalazin-1(2H)-one Derivatives as Melanin Concentrating Hormone Receptor 1 (MCH-R1) AntagonistsBulletin of the Korean Chemical Society, Vol. 34, No. 12Small molecule drug screening in Drosophila identifies the 5HT2A receptor as a feeding modulation target2 July 2013 | Scientific Reports, Vol. 3, No. 1Synthesis and SAR study of pyrrolo[3,4-b]pyridin-7(6H)-one derivatives as melanin concentrating hormone receptor 1 (MCH-R1) antagonistsBioorganic & Medicinal Chemistry Letters, Vol. 23, No. 6Lipolytic proteomics5 March 2012 | Mass Spectrometry Reviews, Vol. 31, No. 5Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons3 August 2012 | Nature Reviews Drug Discovery, Vol. 11, No. 9Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008Annals of Epidemiology, Vol. 22, No. 5 Vol. 3, No. 3 Follow us on social media for the latest updates Metrics Downloaded 618 times History Published online 29 March 2011 Published in print March 2011 Information© Future Science LtdKeywordsadverse effectscost–effectivenessefficacyobesityweight lossFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download